Abstract

BackgroundNo standard treatment protocol exists for Kawasaki disease (KD) after spontaneous defervescence that does not use intravenous immunoglobulin (IVIG). Moreover, some cases present an indolent course and later develop coronary artery lesions (CALs). We aimed herein to assess the short-term prognosis of KD after defervescence and to clarify the characteristics of indolent KD.Study designThe present report is the culmination of a 10-year retrospective cohort study of KD at two Japanese tertiary pediatric centers. Cases of spontaneously defervesced KD ≤ 7 days of illness without IVIG which were afebrile for ≥ 3 days were classified as ‘defervesced KD’ (dKD). Of these, cases which developed CALs, or received IVIG for ongoing systemic inflammation were sub-classified into the indolent KD group (iKD). The primary outcome was the prevalence of CALs.ResultsAmong 968 KD patients, 7.3 % (71/968) fell into the dKD, and 11.2 % (8/71) into the iKD, groups. No difference in CAL prevalence was observed between the dKD group and the KD group treated with IVIG (9.9 % vs. 7.6 %, p value = 0.49). Six of the 8 iKD cases developed CALs between Days 11 and 23 (median 16) of illness. All iKD cases presented recurrent fever or re-elevated CRP; however, there were generally fewer persistent KD symptoms than at diagnosis.ConclusionsThe prognosis of spontaneously defervesced KD was relatively benign. However, indolent cases with ongoing, systemic inflammation developed CALs. In some cases, immediate IVIG use can be withheld as long as recurrent fever and re-elevation of CRP are monitored and supplementary echocardiogram are conducted.

Highlights

  • No standard treatment protocol exists for Kawasaki disease (KD) after spontaneous defervescence that does not use intravenous immunoglobulin (IVIG)

  • No difference in coronary artery lesion (CAL) prevalence was observed between the defervesced KD’ (dKD) group and the KD group treated with IVIG (9.9 % vs. 7.6 %, p value = 0.49)

  • 71 (7.3 %) were cases of dKD, defined by spontaneous defervescence occurring within 7 days of illness and afebrility lasting ≥ 3 days without IVIG or glucocorticoid therapy

Read more

Summary

Introduction

No standard treatment protocol exists for Kawasaki disease (KD) after spontaneous defervescence that does not use intravenous immunoglobulin (IVIG). Some cases present an indolent course and later develop coronary artery lesions (CALs). Kawasaki disease (KD) is an acute, self-limiting, childhood vasculitis marked by a constellation of fever and various acute inflammatory features. These clinical symptoms resolve in on average 11 days without treatment, coronary artery lesions (CALs) may later develop [1]. The optimal management of KD in patients who experience spontaneous defervescence remains uncertain. For this population, the Japanese KD management guidelines recommend that the decision to withhold IVIG should be made after the laboratory test and echocardiography results are considered [2]. While the American Heart Association (AHA) does not suggest withholding IVIG treatment in KD patients presenting ≤ 10 days of illness

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call